Evidence map›Paper›PMID 23824645›Full record

Trial reportMedical oncology (Northwood, London, England)2013

Sorafenib versus capecitabine in the management of advanced hepatocellular carcinoma.

Omar Abdel-Rahman, Manal Abdel-Wahab, Mohammed Shaker, Sherif Abdel-Wahab, Mohammed Elbassiony, Mahmoud Ellithy

Erratum issuedAbstract readClinical Trial, Phase IIRandomized Controlled Trial
PubMed Publisher
In one paragraph

Trial report in Medical oncology (Northwood, London, England), 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 24 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed, 3 pooled it
3.7field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

24 citing papers in PubMed, 3 syntheses or guidelines pooled it, 54 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Article
  5. Article
  6. Transcriptional elongation control of hypoxic response.Proceedings of the National Academy of Sciences of the United States of America · 2024
    Article
  7. Article
  8. Review
  9. Article
  10. Review
  11. Review
  12. AqueousInternational journal of medical sciences · 2020
    Article
  13. Review
  14. Article
  15. Article
  16. Emerging therapies in advanced hepatocellular carcinoma.Experimental hematology & oncology · 2018
    Review
  17. Article
  18. Hepatocellular carcinoma (HCC): beyond sorafenib-chemotherapy.Journal of gastrointestinal oncology · 2017
    Review
  19. Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Omar Abdel-RahmanClinical Oncology Department, Faculty of Medicine, Ain Shams University, Lofty Elsayed Street, Abbaseya, Cairo, Egypt. omar.abdelrhman@med.asu.edu.eg
Manal Abdel-Wahab
Mohammed Shaker
Sherif Abdel-Wahab
Mohammed Elbassiony
Mahmoud Ellithy
Ain Shams University · EG

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The only approved systemic therapy for patients with advanced hepatocellular carcinoma (HCC) till now is sorafenib. A preliminary study suggested that capecitabine, an oral fluoropyrimidine, may be effective in advanced HCC. We have tested this hypothesis in this phase 2 study. In this single-center, phase 2, open-label trial, we randomly assigned 52 patients with advanced HCC who had not received previous systemic treatment to receive either sorafenib (at a dose of 400 mg twice daily) or capecitabine (1,000 mg/m(2) twice daily) (day 1-day 14). Primary outcome was progression-free survival. Secondary outcomes included the overall survival and safety. Median overall survival was 7.05 months in the sorafenib group and 5.07 months in the capecitabine group (hazard ratio in the capecitabine group 2.36; 95 % confidence interval 1.174-4.74; P < 0.016). The median progression-free survival was 6 months in the sorafenib group and 4 months in the capecitabine group (P < 0.005). Three patients in the sorafenib group (11.5 %) and one patient in the capecitabine group (3 %) had a partial response; one patient (3 %) had a complete response in the sorafenib group. Hand-foot skin reaction was more frequent in the sorafenib group, hyperbilirubinemia was more common in the capecitabine group, and diarrhea was equivalent between both groups. In patients with advanced HCC, capecitabine is inferior to sorafenib in terms of median progression-free survival and overall survival, and it should not be used alone for the treatment of advanced HCC, but rather, combination therapy with sorafenib should be considered.

Indexed as

AdultAgedAntimetabolites, AntineoplasticAntineoplastic AgentsCapecitabineCarcinoma, HepatocellularDeoxycytidineDisease-Free SurvivalFluorouracilHumansLiver NeoplasmsMiddle AgedNiacinamidePhenylurea CompoundsSorafenibAntimetabolites, AntineoplasticAntineoplastic AgentsCapecitabineDeoxycytidineFluorouracilNiacinamidePhenylurea CompoundsSorafenib

Identifiers

PMID23824645
OpenAlexW2032995236

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.